Descripción de la empresa
Akso Health Group operates primarily through a social e-commerce mobile platform within the People's Republic of China, offering a diverse range of products including food and beverage items, wine, cosmetics, fashion apparel, and entertainment services via its Xiaobai Maimai App. The company functions within the healthcare sector, specifically classified under the medical distribution industry, which implies a focus on the logistics and supply chain aspects of medical or related consumer goods rather than direct patient care. As of the latest available data, the firm maintains a market capitalization of $1.95B and employs approximately 27 individuals to support its operations. The combination of a $1.95B market cap and $14.84M in annual revenue suggests a significant discrepancy between the company's valuation multiples and its current operational scale, indicating that the market price is largely detached from the tangible annual revenue generated by the business. This valuation structure highlights that the stock price is driven more by speculative factors or historical growth expectations rather than the current flow of income from the 27 employees and the existing revenue stream.
Salud financiera
The financial performance of Akso Health Group is characterized by a trailing twelve-month revenue of $14.84M, which contrasts sharply with a net income of $-135,666,432, revealing a severe cost structure where operating expenses vastly exceed gross profitability. The EBITDA stands at $-1,462,343, further confirming that the company's core operations are generating negative cash earnings before interest, taxes, depreciation, and amortization. Free cash flow is reported at $-169,332,416, which indicates a lack of financial flexibility as the company is consuming cash reserves rather than generating new capital for reinvestment or debt servicing. The company holds $11.13M in cash against $2.06M in debt, resulting in a debt-to-equity ratio of 1.04, which suggests a leveraged balance sheet given the negative earnings that prevent effective equity buildup. Despite the leverage, the current ratio is 1.53, indicating that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline of solvency despite operational losses. Return on Equity is -68.3% and Return on Assets is -1.4%, metrics that collectively reveal a highly ineffective management strategy in terms of capital deployment, as the company fails to generate any positive return on the equity invested or the assets utilized.
Evaluación de valoración
The valuation metrics for Akso Health Group include a trailing P/E ratio of N/A and a forward P/E of N/A, implying that the absence of positive earnings makes traditional earnings-based valuation models inapplicable for assessing the stock's current value. The price-to-book ratio is 9.87, which indicates that the market is pricing the company at nearly ten times its book value, suggesting a substantial premium that is not supported by the current profitability or asset base. Alternative valuation metrics such as a price-to-sales ratio of 131.60 and an EV/EBITDA of -4000.97 further illustrate the extreme disconnect between the company's market price and its fundamental financial performance, suggesting that the stock is priced as a speculative asset rather than a value investment. The 52-week high is $2.50 and the 52-week low is $0.83, meaning the current trading price sits within a range that reflects high volatility and uncertainty regarding future cash flows. The beta value is -0.93, a negative figure that implies the stock's price moves inversely to the broader market, indicating a unique risk profile where the asset does not correlate positively with general market movements.
Growth & Income
Revenue growth year-over-year is recorded at 0.9%, while earnings growth is N/A due to the negative net income, implying that the company is not generating sufficient earnings to support traditional growth metrics or reinvestment strategies. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, meaning any theoretical earnings growth would theoretically be available for reinvestment, though currently, there are no earnings to reinvest. The overall growth and income profile is defined by minimal revenue expansion coupled with significant financial distress, as the company relies on external capital or cash on hand to sustain operations in the absence of positive earnings generation. The combination of a 0.9% revenue increase and negative earnings growth highlights a business model that is struggling to translate top-line sales into bottom-line profitability.